title: Regulators of innate immunity as novel targets for panviral therapeutics.
abstract: Interferons (IFNs) have long been used as an immunomodulatory therapy for a large array of acute and chronic viral infections. However, IFN therapies have been plagued by severe side effects. The discovery of pathogen recognition receptors (PRR) rejuvenated the interest for immunomodulatory therapies. The successes obtained with Toll-like receptor (TLR) agonists in activating immune cells and as adjuvant for prophylactic vaccines against different viruses paved the way to targeted immunomodulatory therapy. Better characterization of pathogen-induced immune disorders and newly discovered regulators of innate immunity have now the potential to specifically withdraw prevailing subversion mechanisms and to transform antiviral treatments by introducing panviral therapeutics with less adverse effects than IFN therapies.
authors.affiliation: Institut de Recherche en Immunologie et en Cancérologie (IRIC), Montréal, Québec, Canada.
authors.forename: Salwa
authors.initials: S
authors.lastname: Es-Saad
authors.forename: Nicolas
authors.initials: N
authors.lastname: Tremblay
authors.forename: Martin
authors.initials: M
authors.lastname: Baril
authors.forename: Daniel
authors.initials: D
authors.lastname: Lamarre
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects*; D007372:Interferons / Q000009:adverse effects / Q000627:therapeutic use; D051193:Toll-Like Receptors; D014777:Virus Diseases / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D014780:Viruses / Q000187:drug effects* / Q000235:genetics / Q000276:immunology
chemical_list: D000998:Antiviral Agents; D051193:Toll-Like Receptors; D007372:Interferons